The KISS1 metastasis suppressor: mechanistic insights and clinical utility.
Nash. Kevin T KT; Welch. Danny R DR
Key Findings
- KISS1 functions as a metastasis‑suppressor in melanoma.
- KISS1 levels could act as a prognostic marker for cancer outcomes.
- Targeting KISS1 is being explored as a potential therapy, but it’s still early‑stage research.
Practical Outcomes
- For biohackers there’s no actionable protocol or dosage to apply; the information is mainly relevant to cancer research and not directly useful for everyday health optimization.
Summary
The review explains that the KISS1 gene and its peptide partner can help stop melanoma cancer cells from spreading and might be useful as a test or future treatment, but it doesn’t give any tips you can use now for health, fitness, or longevity.
Abstract
Melanoma is a highly metastatic cancer that accounts for the majority of skin cancer deaths. Unfortunately, very few improvements have been made during the last 20 years in the management of melanoma metastases, which is the major cause of melanoma deaths. Therefore, identification of molecular targets that can be exploited in the clinic to treat metastatic disease is desperately needed. The KISS1 metastasis suppressor gene has emerged as a promising molecular target for the management of metastatic disease. This review compiles data regarding the molecular and biochemical properties of KISS1 and its cognate receptor, focusing on the properties believed to be most pertinent to the use of KISS1 in the clinical setting. In addition, clinical data that supports KISS1 as having a dual role as a prognostic indicator and a therapeutic target for the management of metastatic disease will be highlighted.
Study Information
pubmed
2006
2006-01-01T00:00:00.000Z
10.2741/1824
90
60